| Literature DB >> 27351934 |
Utako Fujii1, Nobuaki Miyahara1,2, Akihiko Taniguchi1, Koichi Waseda1, Daisuke Morichika1, Etsuko Kurimoto1, Hikari Koga1, Mikio Kataoka1,2, Erwin W Gelfand3, Daniel J Cua4, Akihiko Yoshimura5, Mitsune Tanimoto1, Arihiko Kanehiro1.
Abstract
We recently reported that IL-17A plays a critical role in the development of porcine pancreatic elastase (PPE)-induced emphysema. The proliferation of T-helper type 17 (Th17) cells was induced by IL-23. To determine the contribution of IL-23 to the development of pulmonary emphysema, a mouse model of PPE-induced emphysema was used in which responses of IL-23p19-deficient (IL-23-/-) and wild-type (WT) mice were compared. Intratracheal instillation of PPE induced emphysematous changes in the lungs and was associated with increased levels of IL-23 in lung homogenates. Compared with WT mice, IL-23-/- mice developed significantly lower static compliance values and markedly reduced emphysematous changes on histological analyses after PPE instillation. These changes were associated with lower levels of IL-17A and fewer Th17 cells in the lung. The neutrophilia seen in bronchoalveolar lavage fluid of WT mice was attenuated in IL-23-/- mice, and the reduction was associated with decreased levels of keratinocyte-derived cytokine and macrophage inflammatory protein-2 in bronchoalveolar lavage fluid. Treatment with anti-IL-23p40 monoclonal antibody significantly attenuated PPE-induced emphysematous changes in the lungs of WT mice. These data identify the important contributions of IL-23 to the development of elastase-induced pulmonary inflammation and emphysema, mediated through an IL-23/IL-17 pathway. Targeting IL-23 in emphysema is a potential therapeutic strategy for delaying disease progression.Entities:
Keywords: IL-17; Th17; chronic obstructive pulmonary disease
Mesh:
Substances:
Year: 2016 PMID: 27351934 DOI: 10.1165/rcmb.2016-0015OC
Source DB: PubMed Journal: Am J Respir Cell Mol Biol ISSN: 1044-1549 Impact factor: 6.914